鲁拉西酮
医学
生活质量(医疗保健)
安慰剂
析因分析
萧条(经济学)
健康相关生活质量
生活满意度
随机对照试验
内科学
精神科
精神分裂症(面向对象编程)
抗精神病药
心理学
替代医学
心理治疗师
宏观经济学
护理部
疾病
病理
经济
作者
Carole Dembek,Qi Fan,Xiaoli Niu,Yongcai Mao,Vamshi Ruthwik Anupindi,Kimberly K. Laubmeier,Michael Tocco
标识
DOI:10.1080/03007995.2022.2083400
摘要
Objective The objective of this post-hoc analysis was to assess the impact of lurasidone monotherapy on health-related quality of life (HRQoL) in adults with bipolar depression.Methods Data were analyzed from a 6-week randomized, double-blind (DB), placebo-controlled trial of lurasidone monotherapy (NCT00868699) and a 6-month open label extension (OLE; NCT00868959). Patients who received lurasidone monotherapy or placebo during the DB trial were eligible to continue or switch to lurasidone monotherapy during the OLE. The 16-item Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) was collected at DB baseline, DB week 6/OLE baseline, OLE month 3, and OLE month 6. Effect size (ES) and mean changes from baseline were reported for Q-LES-Q-SF total and item scores during the DB trial and OLE, respectively.Results Of 485 patients in the DB trial (lurasidone monotherapy: n = 323; placebo: n = 162), 316 patients continued or switched to lurasidone monotherapy during the OLE. Significant improvements in Q-LES-Q-SF scores in lurasidone vs. placebo were reported for 13 of 16 items (all p < .05) at DB week 6. The greatest improvements were overall life satisfaction (ES = 0.57), social relationships (0.55), medication satisfaction (0.48), family relationships (0.46), and ability to function in daily life (0.45, all p < .001). Improvements in Q-LES-Q-SF total and item scores were sustained at OLE month 6.Conclusions Treatment with lurasidone provided a significant improvement across HRQoL items including overall life satisfaction, social and family relationships, medication satisfaction, and ability to function in daily life. Improvements were sustained during the 6-month OLE.
科研通智能强力驱动
Strongly Powered by AbleSci AI